Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Milestone Pharmaceuticals Inc. (MIST : NSDQ)

• Company Description    Milestone Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing and commercializing the investigational new drug etripamil for the treatment of cardiovascular indications. The company's lead product candidate consists of MSP-2017, a nasal spray. Milestone Pharmaceuticals Inc. is based in Montr?al, Canada. Number of Employees: 33

• Price / Volume Information    Yesterday's Closing Price: $2.56 Daily Weekly Monthly 20 Day Moving Average: 697,827 shares Shares Outstanding: 53.46 (millions) Market Capitalization: $136.87 (millions) Beta: 0.96 52 Week High: $2.75 52 Week Low: $0.63 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 52.38% 46.67% 12 Week 188.00% 142.24% Year To Date 8.47% 1.59%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1111 DR. FREDERIK-PHILIPS BOULEVARD SUITE 420 - MONTREAL,A8 H4M 2X6 CAN ph: 514-336-0444 fax: - ir@milestonepharma.com http://www.milestonepharma.com

• General Corporate Information    Officers Joseph Oliveto - Chief Executive Officer and Director Robert Wills - Chairman of the Board Amit Hasija - Chief Financial Officer Seth Fischer - Director Lisa M. Giles - Director Peer Information Milestone Pharmaceuticals Inc. (CORR.) Milestone Pharmaceuticals Inc. (RSPI) Milestone Pharmaceuticals Inc. (CGXP) Milestone Pharmaceuticals Inc. (BGEN) Milestone Pharmaceuticals Inc. (GTBP) Milestone Pharmaceuticals Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 59935V107 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/14/25 Share - Related Items Shares Outstanding: 53.46 Most Recent Split Date: (:1) Beta: 0.96 Market Capitalization: $136.87 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.18 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.81 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/14/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -47.62% vs. Previous Quarter: -63.16% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -329.85 12/31/24 - -152.42 ROA 06/30/25 - - 03/31/25 - -67.20 12/31/24 - -48.40 Current Ratio 06/30/25 - - 03/31/25 - 4.67 12/31/24 - 9.10 Quick Ratio 06/30/25 - - 03/31/25 - 4.67 12/31/24 - 9.10 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - -0.11 12/31/24 - 0.25 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - 4.06 Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - 80.23

Powered by Zacks Investment Research ©